Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis

J Thromb Haemost. 2020 Sep;18(9):2358-2363. doi: 10.1111/jth.14992. Epub 2020 Aug 27.

Abstract

Background: A remarkably high incidence of venous thromboembolism (VTE) has been reported among critically ill patients with COVID-19 assisted in the intensive care unit (ICU). However, VTE burden among non-ICU patients hospitalized for COVID-19 that receive guideline-recommended thromboprophylaxis is unknown.

Objectives: To determine the incidence of VTE among non-ICU patients hospitalized for COVID-19 that receive pharmacological thromboprophylaxis.

Methods: We performed a systematic screening for the diagnosis of deep vein thrombosis (DVT) by lower limb vein compression ultrasonography (CUS) in consecutive non-ICU patients hospitalized for COVID-19, independent of the presence of signs or symptoms of DVT. All patients were receiving pharmacological thromboprophylaxis with either enoxaparin or fondaparinux.

Results: The population that we screened consisted of 84 consecutive patients, with a mean age of 67.6 ± 13.5 years and a mean Padua Prediction Score of 5.1 ± 1.6. Seventy-two patients (85.7%) had respiratory insufficiency, required oxygen supplementation, and had reduced mobility or were bedridden. In this cohort, we found 10 cases of DVT, with an incidence of 11.9% (95% confidence interval [CI] 4.98-18.82). Of these, 2 were proximal DVT (incidence rate 2.4%, 95% CI -0.87-5.67) and 8 were distal DVT (incidence rate 9.5%, 95% CI 3.23-5.77). Significant differences between subjects with and without DVT were D-dimer > 3000 µg/L (P < .05), current or previous cancer (P < .05), and need of high flow nasal oxygen therapy and/or non-invasive ventilation (P < .01).

Conclusions: DVT may occur among non-ICU patients hospitalized for COVID-19, despite guideline-recommended thromboprophylaxis.

Keywords: COVID-19; deep vein thrombosis; thromboprophylaxis; venous thromboembolism.

MeSH terms

  • Aged
  • Aged, 80 and over
  • COVID-19 / complications*
  • COVID-19 / epidemiology
  • Enoxaparin / therapeutic use
  • Female
  • Fondaparinux / therapeutic use
  • Guidelines as Topic
  • Hospitalization
  • Humans
  • Incidence
  • Lower Extremity / blood supply
  • Male
  • Middle Aged
  • Ultrasonography
  • Venous Thromboembolism / complications*
  • Venous Thromboembolism / prevention & control*
  • Venous Thrombosis / complications*
  • Venous Thrombosis / prevention & control*

Substances

  • Enoxaparin
  • Fondaparinux